MHC-I has attracted considerable attention as it presents endogenous peptide antigens to CD8+ T cells, inhibits interference with tumor recognition, and reduces CD8+ T cell cytotoxicity, which are primary effector cell types for ICB success (4). The gene discussed is CD8A; the disease is neoplasm.